002365.SZ
Qianjiang Yongan Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 15.11
−8.92%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 847.9M | 783.2M | 838.8M | 972.9M | 1.5B |
| Cost of Revenue | 684.3M | 650.7M | 671.1M | 721.2M | 980.8M |
| Gross Profit | 163.6M | 132.5M | 167.7M | 251.7M | 481.7M |
| Operating Expenses | |||||
| R&D Expense | 31.1M | 30.9M | 37.0M | 41.5M | 40.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 58.9M | 59.7M | 73.4M | 145.2M | 147.3M |
| Selling & Marketing Expense | 44.9M | 40.1M | 17.3M | 54.5M | 125.2M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 149.2M | 140.6M | 127.6M | 244.4M | 305.7M |
| Cost and Expenses | 833.5M | 791.2M | 798.7M | 965.6M | 1.3B |
| Operating Income (EBIT) | 28.4M | 10.6M | 72.9M | 5.6M | 152.4M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 26.8M | 9.9M | 70.9M | 6.1M | 153.1M |
| Income Tax Expense | 5.0M | 2.7M | 11.2M | 34.5M | 20.3M |
| Bottom Line | |||||
| Net Income | 34.6M | 22.5M | 61.8M | (12.3M) | 140.3M |
| Earnings from Cont. Ops | 21.9M | 7.2M | 59.7M | (52.1M) | 109.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 34.6M | 22.5M | 61.8M | (12.3M) | 140.3M |
| Per Share | |||||
| Basic EPS | CN¥0.12 | CN¥0.08 | CN¥0.21 | (CN¥0.04) | CN¥0.48 |
| Diluted EPS | CN¥0.12 | CN¥0.08 | CN¥0.21 | (CN¥0.04) | CN¥0.48 |
| Revenue Per Share | CN¥2.94 | CN¥2.71 | CN¥2.86 | CN¥3.30 | CN¥4.96 |
| Shares | |||||
| Basic Shares Outstanding | 288.7M | 289.5M | 293.1M | 294.6M | 294.7M |
| Diluted Shares Outstanding | 288.7M | 289.5M | 293.1M | 294.6M | 294.7M |
| Profitability Metrics | |||||
| EBITDA | — | 127.5M | 185.8M | 140.8M | 276.0M |
| D&A | — | 116.8M | 112.8M | 135.2M | 123.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026